Chinook Therapeutics Inc. (KDNY)
Chinook Therapeutics Statistics
Share Statistics
Chinook Therapeutics has 67.05M shares outstanding. The number of shares has increased by 43.31% in one year.
| Shares Outstanding | 67.05M |
| Shares Change (YoY) | 43.31% |
| Shares Change (QoQ) | 3.79% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 61.16M |
| Failed to Deliver (FTD) Shares | 2.99K |
| FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 2.88M, so 4.01% of the outstanding shares have been sold short.
| Short Interest | 2.88M |
| Short % of Shares Out | 4.01% |
| Short % of Float | 4.59% |
| Short Ratio (days to cover) | 3.45 |
Valuation Ratios
The PE ratio is -9.14 and the forward PE ratio is null. Chinook Therapeutics's PEG ratio is -0.31.
| PE Ratio | -9.14 |
| Forward PE | n/a |
| PS Ratio | 275.21 |
| Forward PS | n/a |
| PB Ratio | 3.82 |
| P/FCF Ratio | -14.16 |
| PEG Ratio | -0.31 |
Enterprise Valuation
Chinook Therapeutics has an Enterprise Value (EV) of 1.61B.
| EV / Sales | 262.81 |
| EV / EBITDA | -9.81 |
| EV / EBIT | -13.71 |
| EV / FCF | -13.52 |
Financial Position
The company has a current ratio of 7.59, with a Debt / Equity ratio of 0.09.
| Current Ratio | 7.59 |
| Quick Ratio | 7.59 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | -0.24 |
| Debt / FCF | -0.33 |
| Interest Coverage | -25.78 |
Financial Efficiency
Return on Equity is -41.77% and Return on Invested Capital is -39.37%.
| Return on Equity | -41.77% |
| Return on Assets | -32.16% |
| Return on Invested Capital | -39.37% |
| Revenue Per Employee | $28.64K |
| Profits Per Employee | $-862.69K |
| Employee Count | 214 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 4.34M |
| Effective Tax Rate | -2.41% |
Stock Price Statistics
The stock price has increased by 0% in the last 52 weeks. The beta is 0.67, so Chinook Therapeutics's price volatility has been higher than the market average.
| Beta | 0.67 |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 38.59 |
| 200-Day Moving Average | 26.93 |
| Relative Strength Index (RSI) | 78.49 |
| Average Volume (20 Days) | 2.04M |
Income Statement
In the last 12 months, Chinook Therapeutics had revenue of 6.13M and earned -184.62M in profits. Earnings per share was -2.87.
| Revenue | 6.13M |
| Gross Profit | 4.41M |
| Operating Income | -185.08M |
| Net Income | -184.62M |
| EBITDA | -164.2M |
| EBIT | -173.1M |
| Earnings Per Share (EPS) | -2.87 |
Balance Sheet
The company has 115.44M in cash and 39.44M in debt, giving a net cash position of 76M.
| Cash & Cash Equivalents | 115.44M |
| Total Debt | 39.44M |
| Net Cash | 76M |
| Retained Earnings | -419.63M |
| Total Assets | 488.81M |
| Working Capital | 252.94M |
Cash Flow
In the last 12 months, operating cash flow was -117.48M and capital expenditures -1.65M, giving a free cash flow of -119.13M.
| Operating Cash Flow | -117.48M |
| Capital Expenditures | -1.65M |
| Free Cash Flow | -119.13M |
| FCF Per Share | -1.85 |
Margins
Gross margin is 71.9%, with operating and profit margins of -3020.28% and -3012.65%.
| Gross Margin | 71.9% |
| Operating Margin | -3020.28% |
| Pretax Margin | -2941.81% |
| Profit Margin | -3012.65% |
| EBITDA Margin | -2679.44% |
| EBIT Margin | -3020.28% |
| FCF Margin | -1944.09% |
Dividends & Yields
KDNY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -10.95% |
| FCF Yield | -7.06% |
Analyst Forecast
Currently there are no analyst rating for KDNY.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Oct 2, 2020. It was a backward split with a ratio of 1:5.
| Last Split Date | Oct 2, 2020 |
| Split Type | backward |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | 9.7 |
| Piotroski F-Score | 3 |